Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.73 |
| ▸ | RARG | P13631 | 14/20 | 0.73 |
| ▸ | RARB | P10826 | 12/20 | 0.73 |
| ▸ | RARA | P10276 | 11/20 | 0.73 |
| ▸ | RXRB | P28702 | 10/20 | 0.73 |
| ▸ | RXRG | P48443 | 9/20 | 0.73 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177720 | 1.00 | RXRA (0.73) | RXRARARGRARBRARARXRB | |
| SCHEMBL6263321 | 0.85 | RXRA (0.74) | RXRARARGRARBRARARXRB | |
| SCHEMBL6263315 | 0.85 | RXRA (0.74) | RXRARARGRARBRARARXRB | |
| SCHEMBL6428704 | 0.85 | RARB (0.54) | RXRARARGRARBRARARXRB | |
| SCHEMBL4957909 | 0.83 | RXRA (0.75) | RXRARARGRARBRARARXRB | |
| SCHEMBL4957907 | 0.83 | RXRA (0.75) | RXRARARGRARBRARARXRB | |
| SCHEMBL6259440 | 0.81 | RXRA (0.48) | RXRARARGRARBRARARXRB | |
| SCHEMBL6259442 | 0.81 | RXRA (0.48) | RXRARARGRARBRARARXRB | |
| SCHEMBL6428716 | 0.81 | RXRA (0.48) | RXRARARGRARBRARARXRB | |
| SCHEMBL6258870 | 0.80 | RARB (0.70) | RXRARARGRARBRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906057-B1 | Methods for modulating FXR receptor activity | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | claimed |
| EP-2399575-A2 | Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399988-A2 | Cell culture system for replication of HCV through the farnesoid X receptor (FXR) activation or inhibition and diagnostic method for HCV infection | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-08 | — | — | US | disclosed |
| EP-2054065-A2 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008017692-A2 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2008-02-14 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1185277-B1 | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer | ALLERGAN INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6906057-B1 | Methods for modulating FXR receptor activity | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1185539-B1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN INC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6452032-B1 | ANTAGONISTS, AGONISTS, OR INVERSE AGONISTS PARTICULARLY FOR RETINOID AND FARNESOID RECEPTORS; REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION AND OF LIPID METABOLISM; DERMATOSES SUCH AS ACNE, PSORIASIS, ICTHYOSIS AND ECZEMA | ALLERGAN SALES, LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1185539-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | Allergan Sales, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1185277-A1 | METHODS FOR MODULATING FXR RECEPTOR ACTIVITY | Allergan Sales, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076523-A1 | METHODS FOR MODULATING FXR RECEPTOR ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077011-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | RXRA 1819/4885RARG 2458/4885RARB 3352/4885 |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | FXR1, FXR2, NR1H4 | RXRA 125/4885RARG 404/4885RARB 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.